AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04027101
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
Trial: NCT01429077
Drug: levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
Trial: NCT01429077
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
Trial: NCT00280241
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
Trial: NCT00860392
Drug: Stable isotope tracer (13-C(4)-BHB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
Trial: NCT03004339
Drug: SOR007 Ointment 2.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03004339
Drug: SOR007 Ointment 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03004339
Drug: SOR007 Ointment 0.15%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03004339
Drug: SOR007 Ointment Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03004339
Drug: Taclonex® Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00219817
Drug: RC-1291 HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01557517
Drug: Placebo oral rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
Trial: NCT05148377
Drug: Heptar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
Trial: NCT01607853
Drug: Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application, 3 weeks
Trial: NCT01607853
Drug: Daivobet® gel applied for 24 hours (+/- 2 hours)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application, 3 weeks
Trial: NCT00637494
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
Trial: NCT02444910
Drug: KDT501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
Trial: NCT00533312
Drug: Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04335604
Drug: JPI-547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose levels will be escalated following a 3+3 dose escalation scheme.
Trial: NCT04000919
Drug: 5HTP
RxNorm normalized name: GABA/5HTP/caf/arg/chl/br/hb318 1,400 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
Trial: NCT04000919
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03764618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00823940
Drug: GSK1362885
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 - 100mg of GSK1362885 or placebo
Trial: NCT00823940
Drug: GSK1362885
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 - 600mg or placebo
Trial: NCT00626808
Drug: No Intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There were no interventions. No subjects were enrolled in this retrospective database study.
Trial: NCT01602393
Drug: CHF 5074 2x
RxNorm normalized name: Worm Protector 2X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, 2x, once a day in the morning for 48 weeks
Trial: NCT00047112
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03213457
Drug: Estradiol/Norethindrone Acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT03892018
Drug: Oraxol
RxNorm normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
Trial: NCT03105336
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT02229461
Drug: Naproxen Sodium (Aleve, BAY117031)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 220 mg qd or bid
Trial: NCT02229461
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA 81 mg qd
Trial: NCT00676260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks
Trial: NCT02509169
Drug: TAE plus P53 gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-catheter embolization combined with recombinant adenoviral human p53 gene therapy
Trial: NCT00134901
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03685214
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
Trial: NCT01108783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (encapsulated) Tablets QD/14 days
Trial: NCT04476953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo looks exactly like the study drug, but it contains no active ingredient.
Trial: NCT03333265
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months
Trial: NCT03953326
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
Trial: NCT03953326
Drug: L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
Trial: NCT02481869
Drug: Arthrocentesis/Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
Trial: NCT03157635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as per schedule described in Part 1 placebo arm.
Trial: NCT01936350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
Trial: NCT01830595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01111955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, once daily, 28 days
Trial: NCT02641652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial
Trial: NCT03774407
Drug: vaginal estriol
RxNorm normalized name: estriol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol vaginal cream will be formulated by Twin Oaks specialty pharmacy-by the same compound specialist. 30 mg estriol powder will be mixed with 5 mL of propylene glycol and 22 g of vaginal base cream. The product can be stored at room temperature and has a shelf life of up to 4 months. It comes with an applicator.
Trial: NCT00709956
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
Trial: NCT03493412
Drug: Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mg/kg will be used as the dose of BH4
Trial: NCT03493412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03617783
Drug: Prebiotin
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotin (12g/day), an oligofructose-enriched inulin (OEI)
Trial: NCT03617783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo-OEI
Trial: NCT01815359
Drug: EPIC with FUDR and Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01105091
Drug: Flolan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per Prescribing Information
Trial: NCT00391443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
Trial: NCT02553460
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT02553460
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO or NG.
Trial: NCT02553460
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV, IM or PO.
Trial: NCT02553460
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin rescue PO or IV.
Trial: NCT02570282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
Trial: NCT01408602
Drug: MRC375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
Trial: NCT02570282
Drug: SST-6007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
Trial: NCT01408602
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
Trial: NCT03372603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).
Trial: NCT01408602
Drug: MRC375 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
Trial: NCT01028963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules once daily
Trial: NCT01028963
Drug: CCX140-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX140-B capsules once daily (Group C)
Trial: NCT01028963
Drug: CCX140-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX140-B capsules once daily (Group D)
Trial: NCT01199055
Drug: CS-7017
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4\~6 cycles (1 cycle: 3 weeks)
Trial: NCT03084718
Drug: Placebo pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Control
Trial: NCT01308424
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual dosing for 7 days
Trial: NCT01601340
Drug: HQK-1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HQK-1001 tablets, twice daily for 48 weeks
Trial: NCT01696760
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 325 mg twice a day
Trial: NCT01267487
Drug: Heparin fixed doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT \> 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery.
Trial: NCT01267487
Drug: Heparin and protamine titration
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve.
Trial: NCT01332292
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
Trial: NCT04542057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Formulation:~Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks
Trial: NCT00352417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dosing, 1 time daily for 12 weeks
Trial: NCT00396565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
Trial: NCT04607057
Drug: Parenteral Nutrition Solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Day0 : fasting(NPO) + crystalloid fluid~* POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~* POD#2 : Semifluid diet (SFD) + crystalloid fluid~* POD#3 : Semifluid diet (SFD) + PN~* POD#4-7: Soft blended diet (SBD) + PN
Trial: NCT00028977
Drug: herba scutellaria barbata
RxNorm normalized name: Scutellaria barbata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04201197
Drug: Inje cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute drug exposure
Trial: NCT04201197
Drug: THC Cannabis extract
RxNorm normalized name: Cannabis sativa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute drug exposure
Trial: NCT04201197
Drug: THC/CBD Cannabis Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute drug exposure
Trial: NCT04511819
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered with food when possible.
Trial: NCT00893269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive placebo prior to sleep
Trial: NCT01940510
Drug: RO5424802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose without (Day 1) and with (Day 17) co-administration of rifampin
Trial: NCT00986310
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
Trial: NCT00986310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
Trial: NCT03247413
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, normal saline administered post-ablation at each lesion site
Trial: NCT06742216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Trial: NCT03277755
Drug: SMV 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
Trial: NCT01028482
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00619060
Drug: Topical Myristyl Nicotinate Cream
RxNorm normalized name: myristyl nicotinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
Trial: NCT00619060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants apply topical placebo to one forearm once daily for 4 weeks.
Trial: NCT05904002
Drug: pulmicort inhaler
RxNorm normalized name: Pulmicort Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each woman in both groups (A\&B) will receive pulmicort inhaler on needs.
Trial: NCT00745550
Drug: SB1518
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
Trial: NCT01819870
Drug: Dilatrend SR capsule 32mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 1 capsule, oral, once daily, 7days~* over the period I\&II(crossover)
Trial: NCT01819870
Drug: Dilatrend IR tablet 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 1 tablet, oral, once daily, 7days~* over the period I\&II(crossover)
Trial: NCT00142025
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00247494
Drug: mycophenol mofetil (MMF, Cellcept®) 500 mg BID
RxNorm normalized name: mycophenolate mofetil 500 MG
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02299063
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06750445
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the fluoxetine group received oral fluoxetine starting at 40 mg/day for six months. Treatment was discontinued if serious adverse reactions developed or if no improvement was observed after dose escalation. Compliance and treatment progress were monitored via telephone follow-ups. For patients unable to have a bowel movement for three consecutive days or experiencing intolerable symptoms, polyethylene glycol (PEG, 10 g) was provided as rescue medication. Bowel movements within 24 hours of rescue medication use were excluded from the count of complete spontaneous bowel movements (CSBM).
Trial: NCT00424294
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
Trial: NCT00424294
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
Trial: NCT00516425
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00516425
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00361127
Drug: isotonic saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02068131
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
Trial: NCT03508635
Drug: Matching Placebo of CORT125134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02656069
Drug: G-Pen (glucagon injection)
RxNorm normalized name: penicillin G procaine Injectable Suspension [Pro-Pen-G]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
Trial: NCT00578266
Drug: Cyclophosphamide,Campath IH and TBI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAY 5 TREATMENT~* 6 5 CYTOXAN 50 mg/kg WITH MESNA~* 5 CYTOXAN 50 mg/kg WITH MESNA;~* 4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg~* 3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;~* 2 TBI; CAMPATH; TACROLIMUS~* 1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)